Evaxion A/S (EVAX)
NCM · Biotechnology
Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires
Company overview
Evaxion A/S, a clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of advanced melanoma; EVX-03, DNA-based cancer vaccine for the treatment of solid tumors; and EVX-04, a therapeutic cancer vaccine candidate, which is in phase 1 trial for acute myeloid leukemia. Its programs also include vaccines that are in pre-clinical stage, which includes EVX-B1, a multi-component prophylactic vaccine targeting skin and soft tissue infections with S. aureus bacteria; EVX-B2 to target multi-component prophylactic vaccine against gonorrhea bacteria; EVX-B3 to target bacterial pathogen associated with repeated infections; and EVX-V1, a multi-component prophylactic vaccine candidate for cytomegalovirus. The company was formerly known as Evaxion Biotech A/S and changed its name to Evaxion A/S in May 2025. Evaxion A/S was incorporated in 2008 and is based in Horsholm, Denmark.
Peers in Biotechnology
All in industry →Vertex Pharmaceuticals Incorporated
Regeneron Pharmaceuticals, Inc.
argenx SE
Alnylam Pharmaceuticals, Inc.
BeOne Medicines AG
Insmed Incorporated
Royalty Pharma plc
BioNTech SE
Roivant Sciences Ltd.
Moderna, Inc.
Recent press releases
April 2026
Evaxion A/S — 6-K Filing
# 🧾 What This Document Is This is a **6-K filing**, which is a report foreign companies like Evaxion (based in Denmark) must file with the SEC to share material news with U.S. investors. Think of it as a formal press release submitted to regulators. This specific filing announces a clinical trial m
March 2026
Evaxion A/S — 6-K Filing
# 🧾 What This Document Is This is a press release (filed as a 6-K form) announcing that the company, Evaxion, will be presenting new research at a major scientific conference. It’s a way for the company to share exciting news with the public and investors. # 🏢 What The Company Does 👉 In simple t
SEC filings
All filings →Insider trades
All insider trades →Evaxion A/S has no reported insider trades in the last 90 days.
Institutional holders
All holders →No 13F holdings have been reported for Evaxion A/S in this window.